Targeting EMT in Cancer with Repurposed Metabolic Inhibitors

Area of Science:

• Oncology and Cancer Biology
• Metabolic pathways in cancer
• Drug repurposing for cancer therapy

Background:

• Epithelial-to-mesenchymal transition (EMT) drives lethal cancer traits like metastasis and chemoresistance.
• Directly targeting EMT effector molecules is pharmacologically difficult.
• Distinct metabolic circuits are increasingly recognized as crucial for EMT.

Purpose of the Study:

• To propose drug repurposing of metabolism-specific inhibitors to target EMT in cancer.
• To explore the use of FDA-approved or clinically trialed drugs for EMT inhibition.
• To offer a novel strategy for combating aggressive and resistant cancers.

Main Methods:

• Review of emerging research on metabolic circuits in EMT.
• Identification of FDA-approved or clinically trialed metabolism-inhibiting drugs.
• Conceptual framework for combining metabolism inhibitors with standard cancer therapies.

Main Results:

• Metabolic pathways are integral to EMT processes.
• Repurposing metabolism inhibitors presents a viable strategy for EMT targeting.
• Combination therapy may overcome EMT-driven resistance.

Conclusions:

• Metabolism-inhibiting drugs offer a promising avenue for targeting EMT.
• Drug repurposing provides a practical approach to developing new EMT-targeted therapies.
• Combining metabolic inhibitors with immunotherapy or chemotherapy can combat aggressive cancers.